Beauveriolide III (BeauIII) inhibited sterol O-acyltransferases 1 and 2 (SOAT1 and SOAT2), which are endoplasmic reticulum (ER) membrane proteins, in an enzyme-based assay, and selectively inhibited SOAT1 in a cell-based assay using SOAT1-/SOAT2-CHO cells. This discrepancy in SOAT inhibition by BeauIII was investigated. In the enzyme-based assay, BeauIII inhibited SOAT1 and SOAT2 to a similar extent using microsomes prepared from cells disrupted under the strongest sonication condition. In semi-intact SOAT1-/SOAT2-CHO cells prepared by a treatment with digitonin (plasma membrane permeabilized), BeauIII selectively inhibited SOAT1 (IC 50 ; 5.0 µM (SOAT1) vs >90 µM (SOAT2)), while in those treated with saponin (plasma membrane and ER membrane permeabilized), BeauIII inhibited SOAT1 (IC 50 , 1.8 µM) and SOAT2 (5.9 µM). SOAT1-selective inhibition by BeauIII was reproduced in intact ER fractions prepared from SOAT1/SOAT2-CHO cells. A Western blotting analysis revealed that biotinlabeled beauveriolide bound to the SOAT1 protein prepared from SOAT1-CHO cells. We concluded that BeauIII binds to a putative active site responsible for SOAT1 that is located on the cytosolic side of the ER, while BeauIII is not accessible to the corresponding active site for SOAT2 located on the luminal side.
Beauveriolides, fungal metabolites produced by Beauveria sp. FO-6979, were identified as inhibitors of lipid droplet formation in mouse peritoneal macrophages [1] [2] [3] . A study of their mechanism of action revealed that beauveriolides inhibit the synthesis of cholesteryl ester (CE), one of the main constituents of lipid droplets in macrophages, by blocking sterol O-acyltransferase (SOAT, also known as acyl-CoA:cholesterol acyltransferase (ACAT)) activity 4 . Among eight beauveriolides 5 , beauveriolides I and III (BeauI and BeauIII, Fig. 1 ) were found to be the most potent SOAT inhibitors. More importantly, BeauIII was demonstrated to be orally active in atherosclerogenic mouse models, reducing atherosclerotic lesions in the aortae and hearts of apolipoprotein E knockout mice and in low density lipoprotein receptor knockout mice 1, 4 . Furthermore, we prepared a number of beauveriolide derivatives using combinatorial chemistry 1 to examine structure-activity relationships and identified more potent inhibitors 1, [6] [7] [8] [9] [10] [11] [12] . During the derivative study, biotin-labeled beauveriolide (Biotin-Beau, Fig. 1 ) was synthesized and proven to be a useful probe for investigating the functions of SOAT 11 . The enzyme SOAT (EC 2.3.1.26), which catalyzes the synthesis of CE from free cholesterol and long-chain fatty acyl-CoA, is regarded as a promising target for the treatment or prevention of atherosclerosis and hypercholesterolemia 6, 13, 14 . Two SOAT isozymes, SOAT1 and SOAT2, were recently identified in various mammals. SOAT1 is ubiquitously expressed in tissues and cells, while SOAT2 is predominantly expressed in the liver (hepatocytes) and intestines 13 . Both SOAT isozymes are membrane proteins localized in the endoplasmic reticulum (ER), and are assumed to possess several hydrophobic domains that penetrate the ER membrane 15, 16 . However, a consensus does not yet exist for a structural model of SOAT1 and SOAT2 proteins.
Rudel and co-workers established sophisticated cell lines including Chinese hamster ovary (CHO) cells expressing the SOAT1 or SOAT2 gene from the African Green monkey. (SOAT1-CHO cells and SOAT2-CHO cells, respectively) or humans (hSOAT1-CHO cells and hSOAT2-CHO cells, respectively) 17 . We previously examined the selectivity of microbial SOAT inhibitors toward SOAT1 and SOAT2 in enzyme-and cell-based assays using SOAT1-/SOAT2-CHO cells 18 . BeauI and BeauIII inhibited SOAT1 and SOAT2 to a similar extent in the enzyme-based assays using microsomes as an enzyme source, and selectively inhibited SOAT1 in the intact cell-based assay 18 . However, the reason for this discrepancy in SOAT inhibition by BeauI and BeauIII between the enzyme-and intact cell-based assays is unclear.
In the present study, we investigated SOAT isozyme inhibition by BeauIII in semi-intact (perforated) CHO cells and an intact ER fraction prepared from CHO cells in an attempt to explain this discrepancy.
Results
Selectivity of beauveriolides toward SOAT isozymes in cell-and enzyme-based assays. We previously reported that BeauI and BeauIII selectively inhibited SOAT1 in an intact cell-based assay, and inhibited SOAT1 and SOAT2 in a microsome assay as an enzyme source using SOAT1-/SOAT2-CHO cells. When hSOAT1-/hSOAT2-CHO cells were used, the same results were reproduced 18 ; SOAT1-selective inhibition by BeauI and BeauIII in an intact cell-based assay with selectivity indexes (SI; log[IC 50 for SOAT1]/[IC 50 for SOAT2]) of <−1.52 and <−1.59 (SOAT1-selective inhibition; SI <−1.00), and SOAT1 and SOAT2 inhibition in an enzyme assay with SI of 0.46 and 0.13 (dual inhibition; −1.00 ≤ SI ≤+1.00), respectively (Table 1) .
In the enzyme assays, the cell lines were disrupted with a Potter-type homogenizer, and microsomes were prepared from the disrupted cells for use as an enzyme source for the SOAT assay. Our hypothesis is that ER membrane integrity is responsible for the SOAT inhibition selectivity of beauveriolides; in other words, the localization of SOAT active sites in ER membranes, which associate with inhibitors, is distinct in SOAT1 and SOAT2. In order to demonstrate our hypothesis, we investigated the effects of CHO-cell-disrupting conditions on BeauIII selectivity in an enzyme assay. SOAT1-and SOAT2-CHO cells were sonicated for 3 (a total of 3 min, 30-sec sonication and a 30-sec interval), 5, and 10 min, and microsomes were then prepared from cells for use as an enzyme source for the assay. As shown in Fig. 2 , SOAT1 activity was inhibited by BeauIII with similar IC 50 s (2.7, 1.3, and 1.2 µM, respectively), while SOAT2 activity was disruption time-dependently inhibited by BeauIII with IC 50 s of >51, 31, and 6.6 µM, respectively. These results suggest that the strongest condition for cell disruption perturbed the ER membrane integrity (the ER membrane may turn inside out and outside in), thereby allowing BeauIII to access the active site of the SOAT2 isozyme in the damaged ER membrane.
Selectivity of BeauIII toward SOAT isozymes in semi-intact cells.
In order to further demonstrate our hypothesis, BeauIII was tested in semi-intact (perforated) SOAT1-and SOAT2-CHO cells prepared by treatments with digitonin and saponin. The treatment of cells with digitonin only perforates the plasma membrane, which allows large molecules such as fatty acyl-CoA to permeabilize the plasma membrane 19 , whereas the treatment with saponin perforates the plasma membrane and ER membrane 20 . In digitonin-treated cells, the ER membrane structure was intact, allowing ER proteins such as SOAT to maintain their conformation, active site Fig. 3 , in digitonin-treated cells, BeauIII inhibited the SOAT1 isozyme with an IC 50 of 5.0 µM, while the IC 50 for SOAT2 was >90 µM, indicating that the inhibitor is selective to SOAT1 (SI, <−1.26). On the other hand, BeauIII inhibited SOAT1 and SOAT2 in saponin-treated cells, (SI, −0.52) as well as in the enzyme assay (SI, 0.00). Thus, the selective inhibition of BeauIII toward the SOAT1 isozyme was reproduced in digitonin-treated semi-intact cell-based assays, but was lost in saponin-treated semi-intact cells.
Selectivity of BeauIII toward SOAT isozymes in intact ER fractions.
In order to further demonstrate our hypothesis, we attempted to purify intact ER fractions from SOAT1-and SOAT2-CHO cells. SOAT1-/ SOAT2-CHO cells were disrupted by a 3-min sonication, and cell lysates were fractionated in 10 fractions (fr. 1 to fr. 10) with an Optiprep TM density gradient 21 . The measurement of SOAT activity and a Western blot analysis of SOAT proteins in each fraction were performed to identify the ER fraction containing SOAT proteins. As shown in Fig. 4A and B, fractionation patterns were very similar between SOAT1-and SOAT2-CHO cells. SOAT activity correlated well with SOAT proteins. In the SOAT assay using intact ER fractions, fr. 6 (SOAT1-CHO cells) and fr. 5 (SOAT2-CHO cells) were used as an enzyme source to investigate the inhibition of BeauIII. As shown in Interaction between beauveriolide and the SOAT1 protein. The direct interaction between beauveriolide and SOAT1 was investigated. Biotin-Beau 11 showed no effect on CE synthesis in the cell-based assay using SOAT1-/SOAT2-CHO cells (Table 1) because of its low permeability in the plasma membrane. However, Biotin-Beau selectively inhibited SOAT1 in the enzyme assay (SI, −1.12) (Table 1) . Therefore, Biotin-Beau may be employed as a useful bio-probe to investigate interactions between SOAT1 and beauveriolide. Biotin-Beau was attached to acrylamide-based streptavidin beads, and microsomes prepared from SOAT1-CHO cells and AC29 cells (control, SOAT-deficient CHO cells) were applied to the beads. After washing the beads, bound proteins were recovered with Laemmli sample buffer, separated by SDS-PAGE, and stained with the SOAT1 antibody 22 . As shown in Fig. 5 , one band at approximately 53 kDa was clearly observed from SOAT1-CHO cells (lane (2)). However, no protein was observed from control AC29 cells (lane (1)) or control beads (no Biotin-Beau-carrying beads) (lane (3)). These results indicate that beauveriolide directly binds to the SOAT1 protein.
Discussion
Our research group discovered a number of microbial SOAT inhibitors in several screening programs of an enzyme-based assay using rat liver microsomes and a cell-based assay using mouse peritoneal macrophages and SOAT1-/SOAT2-CHO cells 1, 23 . In most SOAT inhibitors tested, except for BeauI and BeauIII, IC 50 values obtained in the cell-based assay and enzyme-based assay were consistent 18 . Inhibitors were classified into three groups from SI values; dual inhibitors (−1.00 ≤ SI ≤+1.00) inhibiting SOAT1 and SOAT2 (e.g. purpactins 18 , avasimibe 24 , and pactimibe 25 ), SOAT1-selective inhibitors (SI, <−1.00) (e.g. Wu-V-23 17 and K-604 26 ), and SOAT2-selective inhibitors (SI, >+1.00) (e.g. pyripyropenes 27 ). Interestingly, BeauI and BeauIII showed unusual characteristics in selectivity; dual inhibition in the enzyme-based assay versus SOAT1-selective inhibition in the intact cell-based assay (Table 1) . This discrepancy prompted us to investigate the effects of beauveriolides on SOAT in more detail.
Intact cells generally maintain membrane structures and functions in every organelle in order to preserve cell integrity. However, when cells are disrupted by homogenization or sonication, membrane structures are altered to cause damage to intrinsic membrane integrity. We hypothesized that the discrepancy in the selectivity of inhibition of beauveriolides toward SOAT isozymes between the intact cell-based assay and enzyme-based assay may be due to altered membrane structures including the localization of the active sites of SOAT isozymes in the ER. The present study supported our hypothesis, namely, BeauIII accesses the active site of SOAT1, but cannot access the active site of SOAT2 in intact ER membranes, resulting in SOAT1-selective inhibition by BeauIII in the intact cell-based assay. These results imply that the methods of cell disruption markedly affect membrane structures and also that SOAT1 and SOAT2 have a distinct topology of active sites associated with BeauIII inhibition in ER membranes. We initially tested several conditions to disrupt SOAT1-/SOAT2-CHO cells. Among the conditions examined, our results strongly suggest that cell disruption conditions affect organelle integrity (Figs 2  and 3 ). Radhakrishnan et al. reported the importance of cell disruption conditions to obtain intact ER membranes 28 . We then attempted to obtain intact ER fractions from SOAT1-/SOAT2-CHO cells in order to confirm SOAT1-selective inhibition by BeauIII. When SOAT-rich ER fractions prepared from 3-min sonicated cells were used as an enzyme source, SOAT1-selective inhibition by BeauIII was reproduced (SI, −1.61) (Fig. 4C) . We considered the cell fractionation procedure to have yielded intact ER fractions, although the SOAT fractions showed broad patterns ( Fig. 4A and B) . This may be because the ER is a heterogenous organelle; 3-min sonicated cells giving intact ER fractions with intrinsic functions to show SOAT1-selective inhibition by BeauIII. On the other hand, 10-min sonicated cells yielded sharp ER fractions at fr. 8 (SOAT1-CHO cells) and fr. 7 (SOAT2-CHO cells) by cell fractionation with the Optiprep TM density gradient ( Supplementary Fig. 1A and B) , which are consistent with the reported patterns 28, 29 . However, SOAT1-selective inhibition by BeauIII became worse (SI, −1.04) (Supplementary Fig. 1C ). These results strongly suggest that the ER is a labile and heterogenous organelle and also that usual cell disruption methods damage ER fractions. In the present study, we concluded that beauveriolide only penetrated the plasma membrane and accessed the active site of SOAT1, which faces the cytosolic side, but was unable to access the active site of SOAT2, which faces the luminal side of the ER membrane. BeauIII penetrated the plasma membrane, but not the ER membrane. ER membranes consist of phosphatidylcholine (>50%), cholesterol (<10%), and sphingomyelin (<10%), while plasma membranes have an almost equal quantity of the three lipids (20~30%) 30, 31 . This subtle compositional difference may affect the permeability of BeauIII. Otherwise, a specific transporter present in plasma membranes only may work on BeauIII. The biological and structural properties of SOAT remain poorly understood because it is an ER membrane protein and very difficult to purify. Furthermore, the crystal structure of SOAT has not yet been reported. Using a molecular biological approach, several groups reported that SOAT proteins were predicted to possess several hydrophobic transmembrane domains 15, 16, [32] [33] [34] [35] [36] . Lin et al. showed that human SOAT1 had seven transmembrane domains in the ER, while human SOAT2 only had two 15, 32 . Furthermore, they suggested that the highly conserved FYXDWWN motif (403-409 in human SOAT1) was important for SOAT1 activity 33 . On the other hand, Joyce et al. demonstrated that African Green monkey SOAT1 and SOAT2 isozymes both had five transmembrane domains 16 . Das et al. recently showed that not only the FYXDWWN motif (377-383 in human SOAT2), but also the HEY motif (460-462 in human SOAT1 and 434-436 in human SOAT2) were essential for the activities of the SOAT1 and SOAT2 isozymes 36 . In addition, they found that some putative active site residues (serine, aspartic acid, histidine, and tyrosine) were essential for the activities of SOAT1 and/or SOAT2 using a point mutation technique 36 . Although there does not appear to be a consensus on the structural model for SOAT isozymes, these results indicate that active site topology in the ER membrane is distinct between SOAT1 and SOAT2.
In the present study, we demonstrated that Biotin-Beau is a practically useful bio-probe to investigate the interaction between SOAT1 and beauveriolide. In the analysis of beauveriolide-binding proteins using Biotin-Beau in microsomes prepared from SOAT1-CHO cells, the SOAT1 protein (53 KDa) was not visualized by Coomassie brilliant blue (CBB) staining. The reason for this may be that the expression level of the SOAT1 protein is very low in SOAT1-CHO cells. No significant differences were observed in CBB-stained proteins between AC29 cells (SOAT-deficient CHO cells) and SOAT1-CHO cells. Therefore, the application of the SOAT1 antibody allowed for the detection of SOAT1 as a beauveriolide-binding protein in the immunostaining analysis (Fig. 5) . This is the first study to reveal the interaction of SOAT with an inhibitor. Furthermore, the cellular localization of beauveriolide and SOAT1 was investigated. Biotin-Beau was colocalized with a restricted area of SOAT1 protein distribution in mouse macrophages ( Supplementary Fig. 2 ).
In summary, we herein elucidated the mechanisms underlying SOAT1-selective inhibition by BeauIII in intact cells and the interaction between SOAT1 and beauveriolide. Thus, microbial SOAT inhibitors are useful not only as a potential drug lead, but also as a bio-probe that will shed light on the unknown structures of SOAT isozymes.
Materials and Methods
Materials. BeauI and BeauIII were purified from the culture broth of the producing fungus Beauveria sp.
FO-6979 according to our established methods ( Supplementary Fig. 3) 1 . Biotin-labeled beauveriolide (BiotinBeau) was synthesized as reported previously ( Supplementary Fig. 3 Preparation of an enzyme source from SOAT1-/SOAT2-CHO cells using a Potter-type homogenizer. An enzyme source from SOAT1-/SOAT2-CHO cells using a Potter-type homogenizer was prepared using our established method 18 . Briefly, SOAT1 or SOAT2-CHO cells (2.0 × 10 8 cells) were homogenized in 5 ml cold buffered sucrose solution (pH 7.2, 100 mM sucrose, 50 mM KCl, 40 mM KH 2 PO 4 , and 30 mM EDTA, hereafter referred to as Buffer A) including protease inhibitors (Complete mini (Roche)) in the Potter-type homogenizer. The microsomal fraction was pelleted by centrifugation at 100,000 × g at 4.0 °C for 1.0 h (TLA110, Beckman Coulter), resuspended in the same buffer at a concentration of 5.0 mg protein/ml, and stored at −80 °C until used.
Preparation of an enzyme source from SOAT1-/SOAT2-CHO cells using a sonication machine. SOAT1 or SOAT2-CHO cells (2.0 × 10 8 cells) were sonicated with a Bioruptor (Biosonics Inc.) in 1 ml cold Buffer A including protease inhibitors for 3.0 (30-sec sonication and a 30-sec interval, three rounds), 5.0 (five rounds), and 10 (ten rounds) min on ice. After cell sonication, the sample as an enzyme source was centrifuged at 8,000 × g for 15 min to remove intact cells and debris and stored at −80 °C until used.
Purification of an intact ER fraction with an OptiPrep
TM density gradient. OptiPrep TM density gradients were performed according to the manufacturer's instructions with minor modifications. OptiPrep (60% iodixanol) was diluted to a final concentration of 45% iodixanol, 100 mM sucrose, 50 mM KCl, 40 mM KH 2 PO 4 , and 30 mM EDTA, as the gradient stock solution. Briefly, SOAT1-or SOAT2-CHO cells (>90% confluent) were washed twice with PBS and then incubated with PBS (500 µl) with 0.0625% trypsin/EDTA at 37 °C for 5.0 min in 5.0% CO 2 . All subsequent operations were performed at 4 °C. After centrifugation at 500 × g for 5.0 min, cell pellets were resuspended in 500 µl of Buffer A and sonicated for 3.0 (30-sec sonication and a 30-sec interval, three rounds) and 10 (ten rounds) min on ice. Disrupted SOAT1-or SOAT2-CHO cells were centrifuged at 3,000 × g for 10 min to remove intact cells and debris. The supernatant was diluted to a total volume of 1.0 ml using Buffer A. A discontinuous Optiprep TM gradient was generated in a tube by overlaying the following Optiprep TM solutions all in Buffer A: 1.2 ml each of 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5, and 30% iodixanol. The gradient was centrifuged using himac CP70G (HITACHI) with a swinging bucket rotor (RPS40T, HITACHI) at 100,000 × g for 16 h and allowed to slow down without the application of a break. Then, one band of membrane was clearly visible in a tube. After centrifugation, 1.2 ml of the fraction was collected from the top of the tube, giving a total of 10 fractions. All 10 fractions of SOAT protein levels and activities were analyzed by an immunoblot analysis (described below) and SOAT assay (described below) to identify intact ER fractions including SOAT proteins. After identifying ER fractions, they were stored at −80 °C until used.
Immunoblotting analysis of SOAT1 and SOAT2. An immunoblotting analysis of SOAT1 and SOAT2 was performed by our established method 22 . Briefly, all 10 fractions (15 μL) isolated with the OptiPrep TM density gradient as described above were added to 2x Laemmli sample buffer and 100 mM dithiothreitol (DTT), and then incubated at room temperature for 30 min. Furthermore, 400 mM iodoacetamide (IAA) was added. After a 30-min incubation at room temperature, 5.0 µl of 1.0 M Tris/HCl (pH 9.2) was added to the mixture, a part of which was applied to SDS-PAGE (10% gel) at a constant current of 20 mA for 1.5 h. Proteins were transferred to a polyvinylidene difluoride membrane (PVDF, Immobilon-P, Millipore, USA) for 1.0 h at 100 V by a Western blot apparatus (MODEL BE-350, BIO CRAFT, Japan). After transfer, the PVDF membrane was blocked with 5.0% skim milk in TBST buffer (20 mM Tris/HCl (pH 7.4), 100 mM NaCl, and 0.10% (v/v) Tween 20) at room temperature for 1.0 h. The PVDF membrane was washed with TBST buffer and then soaked in the primary antibody (anti-SOAT1 or anti-SOAT2 rabbit polyclonal antibody 22 , 1:1000 dilution) in TBST buffer at room temperature for 1.0 h. The primary antibody was then removed, and the PVDF membrane was washed and soaked in the secondary antibody (anti-rabbit IgG conjugated to HRP, 1:1000 dilution) for 1.0 h. After removal of the secondary antibody, the blot was visualized using ECL Western Blotting Detection Reagents (GE Healthcare, USA) and detected using LAS-4000 mini with a Science Lab 2005 software (Fujifilm Co., Japan).
Assay for SOAT1 and SOAT2 activities in microsomes or ER fractions. 
